Gülşah Yamancan

Gülşah Yamancan

Auto-generated profile, based on publicly available information

Gülşah Yamancan

G. Yamancan, MD, Department of Rheumatology, Fırat University Faculty of Medicine, Elazığ, Türkiye

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
NLNihal Lermi
Nihal Lermi
AEALİ EKİN
ALİ EKİN
BYBurcu Yagiz
Burcu Yagiz
FYFatih Yıldırım
Fatih Yıldırım
FAFatih Albayrak
Fatih Albayrak
EDEdiz Dalkılıç
Ediz Dalkılıç

18 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TOTuğba OCAK
Tuğba OCAK
BYBurcu Yagiz
Burcu Yagiz
BOBirol Ocak
Birol Ocak
ÖYÖzge Yoğurtçu
Özge Yoğurtçu
FBFatma Başıbüyük
Fatma Başıbüyük
YPYavuz Pehlivan
Yavuz Pehlivan
Background: Secukinumab is a monoclonal antibody against interleukin 17 approved for patients with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis. Treating axSpA and PsA patients with a history of malignancy is a challenge. While initial results on the applicability of secukinumab in this patient group are positive, the number of studies on this topic remains limited. This study aimed to investigate the drug’s survival time and the efficacy and safety of secukinumab treatment in this specific patient group. Methods: This retrospective study included 30 patients with a history of malignancy who were followed up in rheumatology outpatient clinics in 12 centers throughout Turkey and treated with secukinumab between May 2018 and March 2024 with a diagnosis of axSpA and PsA. Results: The mean follow-up time was 29.8 ± 19.3 months. The drug retention rate was 89.7% after 12 months and 80.6% after 24 months. The most common tumor in our study was papillary thyroid carcinoma (n = 5, 16.7%). During follow-up, local tumor recurrence was observed in a patient with urothelial carcinoma of the bladder. Conclusions: In the largest cohort reported to date, treatment with secukinumab in axSpA and PsA patients with a history of malignancy was not shown to cause oncologic recurrence except for one local tumor recurrence. Drug retention rates were also high, and disease activation and function improved compared to baseline. Therefore, secukinumab could be a safe and effective option for this patient group.

15 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JKJehat KILIÇ
Jehat KILIÇ
GYGülşah Yamancan
Gülşah Yamancan
YDYusuf Doğan
Yusuf Doğan
SŞSümeyye Şahin
Sümeyye Şahin
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Background: Behçet’s disease is a multisystem inflammatory disorder with a variable clinical course. This study evaluated the association between inflammatory indices, clinical involvement, and mortality. Methods: This retrospective study included 444 patients with BD. Clinical characteristics and laboratory data were systematically retrieved from electronic medical record system. Inflammatory indices (NLR, PLR, SII) were calculated to reflect systemic inflammation. In addition, CRP-based composite indices (IBI-NLR and IBI-SII) were derived to integrate cellular and acute-phase inflammatory responses. Disease manifestations, major organ involvement, comorbidities, and mortality were recorded to comprehensively assess disease burden and clinical outcomes. Results: In multivariable analysis, vascular involvement was associated with increased ESR level (OR = 1.013, 95% CI: 1.002–1.024, p = 0.018), and male sex (OR = 3.22, 95% CI: 1.83–5.67, p < 0.001;). ROC analysis showed the highest discriminatory performance for vascular involvement, with IBI-NLR (AUC = 0.624, p < 0.001), IBI-SII (AUC = 0.609, p = 0.001) and NLR (AUC = 0.597, p = 0.004). Moreover, NLR (AUC = 0.571, p = 0.017), IBI-NLR (AUC = 0.576, p = 0.010), and IBI-SII (AUC = 0.562, p = 0.036) had modest discrimination for major organ involvement. In contrast, inflammatory indexes were not predictive for mortality (p > 0.05 for all). Mortality was independently associated with higher creatinine (OR = 1.086, p = 0.048), higher ESR (OR = 1.023, p = 0.046), and lower uric acid levels (OR = 0.454, p = 0.002). Conclusions: Inflammatory indices may not predict mortality in BD but can help identify vascular and major organ involvement. Male sex and ESR level are associated more severe disease, while mortality is associated with renal dysfunction and systemic inflammation in BD.

23 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
BÖBurak Öz
Burak Öz
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
GYGulsah Yamancan
Gulsah Yamancan
YDYusuf Doğan
Yusuf Doğan
RARamazan Fazil Akkoc
Ramazan Fazil Akkoc
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
Background/Objectives: Isthmin-1 (ISM1) is a secreted protein involved in immune regulation, inflammation, and angiogenesis. Although ISM1 has been implicated in chronic inflammatory conditions, its clinical relevance in rheumatoid arthritis (RA) remains unknown. This study aimed to evaluate serum ISM1 levels in RA patients and assess their associations with disease activity, autoantibody status, and inflammatory markers. Methods: This cross-sectional study included 90 RA patients fulfilling the 2010 ACR/EULAR criteria and 30 age- and sex-matched healthy controls. Serum ISM1 concentrations were measured using ELISA. Disease activity was assessed using DAS28-CRP and DAS28-ESR. Statistical analyses included group comparisons, correlation testing, multivariate linear regression, and ROC curve analysis to evaluate the predictive performance of ISM1 for remission or low disease activity. Results: Serum ISM1 levels were significantly lower in RA patients than in controls (454 ± 378 vs. 972 ± 809 ng/L, p < 0.001). ISM1 concentrations were inversely correlated with CRP, ESR, and both DAS28 indices. Multivariate regression confirmed independent associations between lower ISM1 concentrations and higher disease activity. ISM1 levels were significantly reduced in RF- and anti-CCP-positive patients, as well as in treatment-naïve early RA. ROC analysis identified a cut-off value of 673.73 ng/L for predicting remission or low disease activity, with an AUC of 0.713 (95% CI: 0.596–0.820), 100% specificity, and 38.9% sensitivity. Conclusions: This study is the first to demonstrate that serum ISM1 is independently associated with disease activity and autoantibody positivity in RA. High ISM1 levels may serve as a specific indicator of clinical remission or low disease activity, supporting its potential as a non-invasive biomarker for disease monitoring.

28 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
SYServet Yolbas
Servet Yolbas
IGİlyas Gündüz
İlyas Gündüz
MKMahmut Kara
Mahmut Kara
EÇEmrah Çay
Emrah Çay
GYGülşah Yamancan
Gülşah Yamancan
MKMuhammed Köroğlu
Muhammed Köroğlu
Background/Objectives: Delayed diagnosis in psoriatic arthritis (PsA) is associated with significant health consequences. We hypothesize that musculoskeletal (MSK) surgery rates may be higher during the diagnostic delay period. This study aimed to compare the frequency of MSK surgeries in PsA patients during the period of diagnostic delay with the frequency of MSK surgeries post-diagnosis. Methods: This retrospective cohort study included PsA patients who fulfilled CASPAR criteria and were followed up on in our outpatient clinic. The pre-diagnosis symptomatic period was considered as the period of diagnostic delay. Data on MSK surgeries were obtained from patient records. The annual number of surgeries was calculated separately for the diagnostic delay and post-diagnosis periods. Results: The study included 84 PsA patients. The mean diagnostic delay in PsA patients was 7.49 years. During this period, 27.4% of patients underwent at least one MSK surgery. The mean annual number of MSK surgeries was significantly higher during the diagnostic delay period compared to the post-diagnosis period (Z = −3.18, p = 0.001, r = 0.35). Conclusions: Following PsA diagnosis, a reduction in MSK surgery rates was observed compared to during the diagnostic delay period. This suggests that inflammatory symptoms in PsA patients, which could have been managed with medical therapy, may have led to avoidable MSK surgeries. These findings highlight the potential for early diagnosis to reduce the rate of musculoskeletal surgery and associated healthcare costs.

13 December 2024 in Rheumatology Quarterly
Verified
Journal Article
Open access
GYGülşah Yamancan
Gülşah Yamancan
İbrahim Gündüzİbrahim Gündüz
İbrahim Gündüz
AKAylin Dolu Karaca
Aylin Dolu Karaca
YDYusuf Doğan
Yusuf Doğan
MKMEHDİ KARASU
MEHDİ KARASU
AKAhmet Karataş
Ahmet Karataş
Aim:Behçet’s disease (BD) is characterized by the presence of skin and mucosal lesions, systemic inflammation, and vasculitis. The objective of this study was to examine changes in urotensin II (UII) and sclerostin levels in patients with BD and to assess their correlation with atherosclerosis. Material and Methods:The study population comprised 32 patients with BD, 39 with systemic lupus erythematosus, and 30 healthy controls. A series of clinical examinations were conducted, and blood samples were obtained to analyze UII and sclerostin levels by enzyme-linked immunosorbent assay. The carotid intima-media thickness (cIMT) was evaluated using Doppler ultrasonography. Results:UII levels were significantly elevated in the BD group compared with the other groups (p<0.001). Conversely, sclerostin levels were markedly diminished in the BD group (p<0.001). In the BD group, UII levels were positively correlated with cIMT (r=0.513, p<0.001), whereas sclerostin levels were negatively correlated with cIMT (r=-0.270, p=0.020). Conclusion:Elevated UII and reduced sclerostin levels are crucial biomarkers of atherosclerosis risk in individuals with BD. These findings help to elucidate the cardiovascular complications associated with BD.